Jeff Yass’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Jeff Yass’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-28,300	Closed	-$3.72M	–	13238
2020 Q4	$3.72M	Sell	28,300 -30,700	-52%	-$2.71M	﹤0.01%	3935
2020 Q3	$2.98M	Buy	+59,000	New	+$2.65M	﹤0.01%	3872
2020 Q2	–	Sell	-55,000	Closed	-$2.69M	–	11361
2020 Q1	$2.69M	Sell	55,000 -19,100	-26%	-$973K	﹤0.01%	3465
2019 Q4	$4.25M	Buy	+74,100	New	+$3.67M	﹤0.01%	3211

Jeff Yass's EIDX Position: Q1 2021 in Review

Jeff Yass sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 4,560 shares — an estimated $600K sold.

Jeff Yass first reported a position in EIDX in Q3 2018 and held it in 6 quarters. The position peaked at $1.93M in Q2 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Jeff Yass reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Jeff Yass sold 4,560 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $600K.
Jeff Yass first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 6 quarters.
Jeff Yass's Eidos Therapeutics, Inc. Common Stock position peaked at $1.93M in Q2 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Susquehanna International Group's 13F filing for Q1 2021, filed 17 May 2021.